Experimental CAR-T therapy takes on lupus and other autoimmune diseases
NCT ID NCT06680388
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a personalized immune cell therapy called CD19 CAR-T in 15 people with severe autoimmune diseases like lupus and scleroderma that haven't responded to standard treatments. The therapy aims to temporarily deplete certain immune cells to calm the overactive immune system. The main goal is to check safety and see if it helps control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD19 CAR-T (a type of immune cell therapy that targets and destroys certain immune cells)
- What this could lead to
- If it works, this could point toward a new treatment option for people with severe autoimmune diseases that don't respond to standard therapies.
- What could go wrong
- This is a very early, small trial with only 15 participants, so results may not apply broadly. There are risks of serious side effects like cytokine release syndrome or neurological issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese Academy of Medical Sciences Hospital of Hematology (Chinese Academy of Medical Sciences Institute of Hematology), Tianjin, 300020
RECRUITINGTianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.